Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills (MAID)

15. november 2026 oppdatert av: Zhang Yun, Qilu Hospital of Shandong University

Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills(MAID)

Objective: To investigate the effect of Compound Danshen Dripping Pills (CDDP)on improving coronary flow reserve(CFR) in patients with coronary microvascular disease (CMVD) and to evaluate their efficacy and safety.

Study Design: Randomized, double-blind, placebo-controlled, multicenter clinical trial.

Study population: Patients with ischemia-related CMVD and myocardial infarction-related CMVD.

Intervention:Treatment group:standard therapy plus CDDP, Twenty pills (27 mg each) orally, three times daily after meals.Control group:standard therapy plus matching placebo, Twenty pills (27 mg each) orally, three times daily after meals.Treatment duration 12 months.

Primary Endpoint: Change in CFRmax from baseline to Month 12 (ΔCFRmax-12m) by Transthoracic Doppler echocardiography(TTE).

Studieoversikt

Detaljert beskrivelse

Rationale for the Study:Coronary Microvascular Disease (CMVD) is a clinical syndrome manifested as effort-induced angina pectoris or laboratory evidence of myocardial ischemia, which results from structural and/or functional abnormalities of the coronary pre-arterioles and arterioles under the effects of multiple pathogenic factors. Impaired coronary microcirculatory function is closely associated with long-term clinical outcomes in patients. A reduced coronary flow reserve (CFR) is not only associated with persistent angina, decreased exercise tolerance, and impaired quality of life, but also independently predicts the risk of cardiovascular death, non-fatal myocardial infarction, heart failure hospitalization, and major adverse cardiovascular events (MACE).Current domestic and international guidelines recommend risk factor control and anti-ischemic therapy as the foundational treatment for CMVD. However, the pathogenesis of CMVD is complex, involving multiple pathological processes such as endothelial dysfunction, microvascular spasm, microvascular remodeling, and inflammation. There is considerable heterogeneity in the treatment benefits among different patients, and evidence-based therapeutic strategies that can definitively improve coronary microcirculatory function and delay disease progression are still lacking.

Basic and clinical studies have demonstrated that the Chinese medicinal compound Compound Danshen Dripping Pills (CDDP) can improve vascular endothelial function and relieve angina pectoris, and it has been widely applied in clinical practice. In the preliminary study entitled Clinical Study on the Effect of Compound Danshen Dripping Pills on Coronary Flow Reserve in Patients with Coronary Microvascular Angina, CDDP effectively improved coronary flow reserve in patients with CMVD. These findings support the value of conducting larger-scale clinical studies to explore its clinical efficacy for CMVD, symptom improvement, and effects measured by the Seattle Angina Questionnaire.

Objective: To investigate the effect of Compound Danshen Dripping Pills (CDDP)on improving coronary flow reserve(CFR) in patients with coronary microvascular disease (CMVD) and to evaluate their efficacy and safety.

Hypothesis: In patients with CMVD receiving standard anti-ischemic therapy, treatment with CDDP for 12 months will significantly improve CFR, reduce major adverse cardiovascular events(MACE), and improve quality of life compared with placebo.

This study adopts a stratified-block randomization design. A total of 496 study participants were divided into two subgroups according to disease diagnosis (Subgroup A: Ischemia-related CMVD; Subgroup B: Myocardial infarction-related CMVD, 248 participants in each subgroup). After the classification of participants into disease-specific subgroups, the system automatically activated the block allocation module corresponding to each subgroup. Participants were assigned to pre-defined groups sequentially according to the real-time enrollment order until the full quota of the subgroup was fulfilled.

During the study, a total of 5 visits will be conducted (Baseline/Screening, Month 3, Month 6, Month 9, and Month 12). At each visit, clinical data will be collected, along with an electrocardiogram (ECG), Canadian Cardiovascular Society (CCS) angina grading, and Seattle Angina Questionnaire (SAQ) scoring. Laboratory tests and echocardiography (including CFR assessment) will be performed at Baseline/Screening, Month 6, and Month 12.

Blood Sampling Protocol: Fasting venous blood samples will be collected at the clinical laboratory of Qilu Hospital of Shandong University on the mornings of the Baseline, Month 6, and Month 12 visits. A total of 3 samples will be collected, with 10 mL drawn each time (total volume: 30 mL). All samples will be sent to the clinical laboratory of Qilu Hospital of Shandong University.

Laboratory Assessments: The blood samples will first be used for routine clinical laboratory tests, including complete blood count (CBC), urinalysis, liver function (ALT, AST), renal function (serum creatinine, urea/BUN), coagulation panel (PT, APTT, TT, FIB), lipid profile (TC, TG, LDL-C, HDL-C), and myocardial enzymes (troponin T [TnT], creatine kinase [CK]). The remaining samples will be utilized for exploratory assessments, such as the detection of inflammatory and endothelial biomarkers, as well as omics screening. Any residual blood samples after the aforementioned tests will be stored uniformly in the cardiovascular laboratory for further exploratory testing in the future.

This study is a large-sample RCT clinical trial targeting CMVD, and is expected to provide evidence-based medical evidence for the treatment of CMVD.

Studietype

Intervensjonell

Registrering (Antatt)

496

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Shandong
      • Jinan, Shandong, Kina, 250000
        • Rekruttering
        • Qilu Hospital of Shandong University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yun Zhang, MD,PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female participants aged 18 to 80 years (inclusive).
  2. Within 6 months prior to randomization, coronary CTA, cardiac MRI, or invasive coronary angiography demonstrating coronary stenosis ≤50%; or residual coronary stenosis ≤50% post-revascularization; or coronary stenosis >50% with FFR >0.80.
  3. CFR of the left anterior descending(LAD) artery measured by transthoracic Doppler echocardiography(TTE) <2.5.
  4. Clinical diagnosis of CMVD, meeting any one of the following categories:

(1)Ischemia-related CMVD:

  • Myocardial Ischemia with Non-Obstructive Coronary Arteries: Presence of symptoms consistent with chronic myocardial ischemia, together with objective evidence of reduced CFR and/or coronary microvascular spasm, in the absence of obstructive epicardial coronary artery disease.

    ②Myocardial Ischemia with obstructive Coronary Arteries: Following successful treatment of epicardial coronary artery stenosis with residual luminal stenosis ≤50%, TTE demonstrates persistent impairment of CFR <2.5 in the LAD.

    (2)Myocardial infarction-related CMVD:

  • Myocardial infarction with non-obstructive coronary arteries (MINOCA): coronary stenosis ≤50% by coronary CTA, cardiac MRI, or invasive coronary angiography.

    • Myocardial infarction with obstructive coronary arteries (MIOCA): Typically associated with coronary microvascular obstruction, including but not limited to ST-segment elevation myocardial infarction (STEMI) complicated by coronary microvascular obstruction.

      5.Voluntary provision of written informed consent by the subject or legal representative.

Exclusion Criteria:

  1. Persistent or permanent atrial fibrillation; clinically significant bradyarrhythmias (including severe sinus bradycardia or second-degree type II or higher atrioventricular block); sinus node dysfunction; uncontrolled chronic obstructive pulmonary disease (COPD); or uncontrolled bronchial asthma.
  2. Severe valvular heart disease, cardiomyopathy, LVEF <50%, Takayasu arteritis, or aortic dissection.
  3. Acute myocardial infarction within 1 month prior to randomization.
  4. Unstable angina within 1 week prior to randomization.
  5. Hemorrhagic stroke within the previous 6 months.
  6. Uncontrolled hypertension, defined as systolic blood pressure (SBP) >150 mmHg and/or diastolic blood pressure (DBP) >90 mmHg despite appropriate medical management.
  7. Hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2 ×ULN) or renal impairment (estimated glomerular filtration rate [eGFR] ≤60 mL/min/1.73m²).
  8. Pregnant, planning pregnancy, or breastfeeding.
  9. Clinically significant respiratory, gastrointestinal, hematologic, infectious, immunologic, endocrine, neurological, psychiatric, or malignant diseases that, in the investigator's judgment, may pose an unacceptable risk to the participant or interfere with study participation.
  10. Current requirement for anticoagulation therapy with warfarin; current use of nicorandil; or concomitant treatment with other traditional Chinese medicine (TCM) preparations.
  11. Active bleeding or clinically significant bleeding tendency, including platelet count <50×10⁹/L or documented coagulation disorders.
  12. Known or suspected hypersensitivity to intra-arterial contrast media, blood or blood products, or the investigational medicinal product.
  13. Participation in another interventional clinical trial within 3 months prior to randomization or concurrent participation in another clinical study.
  14. Any other medical condition or circumstance that, in the opinion of the investigator, would make the participant unsuitable for enrollment in this study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Conventional treatment + Compound Danshen Dripping Pills 540 mg

Participants receive conventional treatment plus Compound Danshen Dripping Pills (CDDP), 20 pills (540 mg) orally three times daily for 12 months.

20 pills (540 mg) orally three times daily for 12 months. Each pill weighs 27 mg, containing Radix Salviae miltiorrhizae, Radix Notoginseng, and Borneolum Syntheticum. Manufactured and supplied by Tasly Pharmaceutical Group Co., Ltd.

Andre navn:
  • CDDP
  • Fufang Danshen Diwan
  • Cardiotonic Pill
  • Dantonic Pill
  • T89
Placebo komparator: Conventional treatment + matching placebo

Participants receive conventional treatment plus placebo pills matching CDDP in appearance, 20 pills orally three times daily for 12 months.

Placebo pills identical to Compound Danshen Dripping Pills in appearance, taste, and packaging, 20 pills orally three times daily for 12 months.

Andre navn:
  • Matchende placebo

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in peak coronary flow reserve (CFRmax) of the left anterior descending artery
Tidsramme: Baseline, 6 months, and 12 months

CFRmax is defined as the ratio of hyperemic to basal peak diastolic flow velocity (PDV) in the mid-to-distal left anterior descending artery, measured by transthoracic Doppler echocardiography (TTDE) during regadenoson-induced maximal hyperemia (regadenoson 0.4 mg/5 mL administered as a single intravenous bolus over approximately 10 seconds, followed by a saline flush). Measurements are performed at baseline, 6 months, and 12 months. Change from baseline at each time point is calculated as the value at that time point minus the baseline value. The primary analysis time point is 12 months.

Baseline, 6 months, and 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in mean coronary flow reserve (CFRmean) of the left anterior descending artery
Tidsramme: Baseline, 6 months, and 12 months

CFRmean is defined as the ratio of hyperemic to basal mean diastolic flow velocity (MDV) in the mid-to-distal left anterior descending artery, measured by transthoracic Doppler echocardiography (TTDE) during regadenoson-induced maximal hyperemia (regadenoson 0.4 mg/5 mL administered as a single intravenous bolus over approximately 10 seconds, followed by a saline flush). Measurements are performed at baseline, 6 months, and 12 months. Change from baseline at each time point is calculated as the value at that time point minus the baseline value.

Baseline, 6 months, and 12 months
Change from baseline in Seattle Angina Questionnaire (SAQ) score
Tidsramme: Baseline, 3, 6, 9, and 12 months

The Seattle Angina Questionnaire (SAQ) is a disease-specific health status measure for coronary artery disease. Each of its five domains (Physical Limitation, Anginal Stability, Anginal Frequency, Treatment Satisfaction, and Disease Perception/Quality of Life) is scored from 0 to 100, with higher scores indicating better health status (fewer symptoms/limitations). Change from baseline is calculated as the score at each time point minus the baseline score.

Baseline, 3, 6, 9, and 12 months
Change from baseline in CCS angina class
Tidsramme: Baseline, 3, 6, 9, and 12 months

Angina severity is classified by the Canadian Cardiovascular Society (CCS) angina classification, ranging from Class I (angina only during strenuous exertion; least severe) to Class IV (angina at rest; most severe), where a higher class indicates a worse outcome. Improvement is defined as a reduction of ≥1 CCS class grade from baseline at each assessment time point.

Baseline, 3, 6, 9, and 12 months
Incidence of major adverse cardiovascular events (MACE) within 12 months
Tidsramme: From randomization/enrollment through 12 months

MACE is a composite endpoint defined as the occurrence of any of the following components during the 12-month follow-up period: (1) cardiovascular death; (2) non-fatal myocardial infarction; (3) revascularization; (4) hospitalization for angina pectoris; and (5) hospitalization for heart failure.

From randomization/enrollment through 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Yun Zhang, MD,PhD, Department of Cardiology,Qilu Hospital of Shandong University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. november 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

12. oktober 2026

Først innsendt som oppfylte QC-kriteriene

20. oktober 2026

Først lagt ut (Faktiske)

21. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared. The informed consent form approved by the ethics committee and signed by participants did not include provisions for sharing de-identified individual participant data beyond the research team or with external investigators, and additional consent for data sharing was not obtained at the time of enrollment.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere